Mobile

A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016973-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the safety and tolerability of orally administered LX1606 in subjects with symptomatic carcinoid syndrome.

Critère d'inclusion

  • Symptomatic Carcinoid Syndrome

Liens